TY - JOUR
T1 - Acute intradialytic well-being
T2 - Results of a clinical trial comparing polysulfone with cuprophan
AU - Mingardi, Giulio
AU - Rota, Stefano
AU - Orlandini, Giancarlo
AU - Misiani, Rocco
AU - Bernareggi, Stefania
AU - Facci, Ornella
AU - Marchesi, Donatella
AU - Bonetti, Luca
AU - Schieppati, Arrigo
AU - Benigni, Ariela
AU - Piccinelli, Antonella
AU - Gualandris, Lucio
AU - Licini, Romana
AU - Mangili, Aristide
AU - Mecca, Giuliano
AU - Poletti, Enza
AU - Tiraboschi, Giacomo
AU - Grassi, Claudio
AU - Bracchi, Oscar
AU - Pedroni, Giovanni
AU - Meterangelis, Agnese
AU - Lorenz, Marco
AU - Ondei, Patrizia
AU - Pedrini, Luciano
AU - Cozzi, Giorgio
AU - Faranna, Pietro
AU - Borghi, Marcello
AU - Vendramin, Giovanni
AU - Massazza, Margherita
AU - Rusconi, Luciano
AU - Giuliano, Patrizia
PY - 1991/10
Y1 - 1991/10
N2 - We conducted a multicenter, randomized, double-blind, controlled clinical trial to compare the effects of a synthetic, high-flux polysulfone membrane with a standard cuprophan one on acute clinical complications during a diffusive dialysis procedure. The principal end-point, that is, the number of hypotensive episodes, was similar in polysulfone (39; 23.8%) and cuprophan (32; 19.5%). Likewise, no significant difference was found between the two membranes as far as the secondary end-point was concerned, that is, the effect on headache, nausea, pruritus and sense of well-being. We conclude that high-flux polysulfone, acutely used in standard diffusive dialysis, has no favorable influence on hypotensive episodes and does not affect some typical dialysis-related symptoms any differently from cuprophan membrane. The need is stressed for well-controlled studies specifically designed to assess the worth of new dialysis techniques and materials that may vastly raise the cost of dialysis treatment.
AB - We conducted a multicenter, randomized, double-blind, controlled clinical trial to compare the effects of a synthetic, high-flux polysulfone membrane with a standard cuprophan one on acute clinical complications during a diffusive dialysis procedure. The principal end-point, that is, the number of hypotensive episodes, was similar in polysulfone (39; 23.8%) and cuprophan (32; 19.5%). Likewise, no significant difference was found between the two membranes as far as the secondary end-point was concerned, that is, the effect on headache, nausea, pruritus and sense of well-being. We conclude that high-flux polysulfone, acutely used in standard diffusive dialysis, has no favorable influence on hypotensive episodes and does not affect some typical dialysis-related symptoms any differently from cuprophan membrane. The need is stressed for well-controlled studies specifically designed to assess the worth of new dialysis techniques and materials that may vastly raise the cost of dialysis treatment.
UR - http://www.scopus.com/inward/record.url?scp=0026077307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026077307&partnerID=8YFLogxK
M3 - Article
C2 - 1745022
AN - SCOPUS:0026077307
VL - 40
SP - 714
EP - 719
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 4
ER -